Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

NAT2 and Bladder Cancer—Response

Beate Pesch, Thomas Bruening and Paolo Vineis
Beate Pesch
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, Germany; 2Imperial College, London, United Kingdom; and 3HuGeF Foundation, Torino, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Bruening
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, Germany; 2Imperial College, London, United Kingdom; and 3HuGeF Foundation, Torino, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Vineis
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, Germany; 2Imperial College, London, United Kingdom; and 3HuGeF Foundation, Torino, Italy
1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, Germany; 2Imperial College, London, United Kingdom; and 3HuGeF Foundation, Torino, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-13-1349 Published March 2014
  • Article
  • Info & Metrics
  • PDF
Loading

Golka and colleagues (1) critically refer to our observation that NAT2 genotype had no impact on bladder cancer risk (2). We were able to demonstrate in our case–control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) that occupational exposure to aromatic amines and polycyclic aromatic amines was associated with an increased bladder cancer risk. On the basis of the comprehensive genotyping of N-acetyltransferase 2 (NAT2), we observed that NAT2 slow acetylation was not itself associated with bladder cancer risk. Notably, our main effect of 1.02 [95% confidence interval (CI), 0.81–1.29] is clearly in line with the OR of 1.02 (95% CI, 0.87–1.19) for a tagging single-nucleotide polymorphism that the authors reported from a pooled analysis of their own studies (3).

We fully recognize that EPIC is a population-based cohort with a low prevalence of rare occupations known to entail a bladder cancer risk. We also mentioned in the article that the metabolism of aromatic amines and the genetic variation of enzymes active in these pathways are more complex than can be captured by a deduced slow or fast acetylator phenotype. We cannot exclude the presence of interactions of N-acetylation with rare exposures to particular aromatic amines. Unfortunately, even very large studies have a limited statistical power to go further into details, i.e., refining the N-acetylation status, finding an association with other polymorphic enzymes, and performing accurate assessment of exposure to (rare) arylmonoamines or aryldiamines. Overall, however, our results do not provide evidence for a strong interaction with occupational exposure.

Golka et al. (1) addressed the decreased bladder cancer risk of slow acetylators in Chinese benzidine-exposed workers (4, 5), whereas studies in German chemical workers showed an increased risk. They attributed this opposite effect to ethnic differences in NAT2 minor allele frequencies (6). However, the decreased risk in benzidine workers may also be explained by differences in the metabolism of arylmonoamines and aryldiamines (4, 7). We will continue exploring the role of NAT2 in the German cohort study UroScreen in chemical workers with more detailed exposure information about aromatic amines (8).

Genetic testing for the polymorphic gene NAT2 was introduced for purposes of compensation or preventive activities among workers with exposure to aromatic amines, but has been criticized because of ethical questions and insufficient scientific evidence (9). Golka et al. (1) considered our conclusion that testing workers for NAT2 would be inappropriate as an overinterpretation. We still consider it premature to test chemical workers for genetic predisposition not only due to uncertain evidence on the excess risk but especially facing the very low-positive predictive value of NAT2 slow acetylation and other biomarkers in bladder cancer due to the low incidence of this disease (8, 10).

See the original Letter to the Editor, p. 561

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received December 19, 2013.
  • Accepted December 19, 2013.
  • ©2013 American Association for Cancer Research.

References

  1. 1.↵
    1. Golka K,
    2. Blaszkewicz M,
    3. Selinski S,
    4. Hengstler JG,
    5. Bolt HM
    . NAT2 and bladder cancer—letter. Cancer Epidemiol Biomarkers Prev 2014;23:561.
    OpenUrl
  2. 2.↵
    1. Pesch B,
    2. Gawrych K,
    3. Rabstein S,
    4. Weiss T,
    5. Casjens S,
    6. Rihs HP,
    7. et al.
    N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort. Cancer Epidemiol Biomarkers Prev 2013;22:2055–65.
    OpenUrl
  3. 3.↵
    1. Schwender H,
    2. Selinski S,
    3. Blaszkewicz M,
    4. Marchan R,
    5. Ickstadt K,
    6. Golka K,
    7. et al.
    Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers. PLoS ONE 2012;7:e51880.
    OpenUrlPubMed
  4. 4.↵
    1. Carreon T,
    2. Ruder AM,
    3. Schulte PA,
    4. Hayes RB,
    5. Rothman N,
    6. Waters M,
    7. et al.
    NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer 2006;118:161–8.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Hayes RB,
    2. Bi W,
    3. Rothman N,
    4. Broly F,
    5. Caporaso N,
    6. Feng P,
    7. et al.
    N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993;14:675–8.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Golka K,
    2. Prior V,
    3. Blaszkewicz M,
    4. Bolt HM
    . The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 2002;128:229–41.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Rothman N,
    2. Garcia-Closas M,
    3. Hein DW
    . Commentary: reflections on G.M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned. Int J Epidemiol 2007;36:23–8.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Pesch B,
    2. Taeger D,
    3. Johnen G,
    4. Gawrych K,
    5. Bonberg N,
    6. Schwentner C,
    7. et al.
    Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health. 2013 Oct 16. [Epub ahead of print].
  9. 9.↵
    1. Vineis P,
    2. Schulte PA
    . Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J Clin Epidemiol 1995;48:189–97.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Kraft P,
    2. Wacholder S,
    3. Cornelis MC,
    4. Hu FB,
    5. Hayes RB,
    6. Thomas G,
    7. et al.
    Beyond odds ratios–communicating disease risk based on genetic profiles. Nat Rev Genet 2009;10:264–9.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 23 (3)
March 2014
Volume 23, Issue 3
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
NAT2 and Bladder Cancer—Response
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NAT2 and Bladder Cancer—Response
Beate Pesch, Thomas Bruening and Paolo Vineis
Cancer Epidemiol Biomarkers Prev March 1 2014 (23) (3) 562; DOI: 10.1158/1055-9965.EPI-13-1349

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NAT2 and Bladder Cancer—Response
Beate Pesch, Thomas Bruening and Paolo Vineis
Cancer Epidemiol Biomarkers Prev March 1 2014 (23) (3) 562; DOI: 10.1158/1055-9965.EPI-13-1349
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Copy Number Variation and Ovarian Cancer Risk—Letter
  • Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk—Response
  • Shift Work, Chronotype, and Cancer Risk—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement